Response: We appreciate the thoughtful comments that supported the inclusion of MIPS Q503: Patient Activation Measure (PAM) in the ASM quality measure set
But because the landscape around compounded GLP-1 medications has shifted dramatically since the FDA resolved the semaglutide shortage in February 2025, and what was once a straightforward decision now involves regulatory gray areas, legal battles, and quality control questions that most people never expected to navigate
AOD-9604 5MG GHK-CU/BPC-157/TB-500 GLOW Blend GLOW Blend (GHK-Cu, BPC-157, TB-500) is a research-grade peptide formulation containing ~70 mg per vial and verified at 99% purity
GHK peptide follicle regeneration GHK (glycyl-histidyl-lysine) is a copper-binding tripeptide that stimulates dermal papilla cell proliferation and protects them from apoptosis
Several commenters requested that CMS update Medicare.gov and related beneficiary-facing resources to include virtual suppliers in provider directories
Where can I find published research on tesamorelin